Fox Rothschild Represents Advanced BioInformatics GmbH in Exclusive Worldwide IP Rights Deal to Develop Novel Cardiac Rhythm Management TechnologiesMay 11, 2020 – Press Releases
Fox Rothschild LLP attorneys Loren David Danzis served as counsel to Advanced BioInformatics GmbH (ABI) to secure exclusive worldwide intellectual property rights from the University of Utah Research Foundation to develop novel cardiac rhythm management solutions based on proprietary low-energy pacing technology.
ABI is an international medical technology company working to develop next-generation cardiac management solutions for patients with significantly fewer complications and side effects than current standards of care.
“We look forward to efficiently advancing our pre-clinical work and initiating formal clinical studies as expeditiously as possible while in parallel exploring partnering opportunities with leading implantable cardiac defibrillator manufacturers around the world,” said J. Todd Derbin, Managing Director and Co-Founder of ABI.
“We believe an unmet medical need exists with these patients who desire a better therapeutic option, and we plan to work diligently toward that goal,” added ABI Managing Director and Co-Founder Volker Brand.
The Fox team was led by Danzis, Chair of the Life Sciences Practice Group and a Partner in the Corporate Department, who has particular experience in venture capital, mergers and acquisitions and commercial contract negotiations.